Paolo A. Tomasi

Paolo A. Tomasi

Auto-generated profile, based on publicly available information

Paolo A. Tomasi

European Medicines Agency, London, United Kingdom

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Human Reproduction
Verified
Journal Article
Open access
PDF file
GMGianfranco Meloni
Gianfranco Meloni
SDS. Dessole
S. Dessole
NVN. Vargiu
N. Vargiu
PTP.A. Tomasi
P.A. Tomasi
SMS. Musumeci
S. Musumeci
An increased incidence of reproductive problems, including infertility, miscarriage, low birth weight newborns, and shorter duration of breast-feeding, are known to exist in women with coeliac disease; some of these conditions are improved by a gluten-free diet. We have tried to ascertain the prevalence of coeliac disease in 99 couples who were being evaluated for infertility, compared with the known prevalence of silent disease in the population of Northern Sardinia, in which it is endemic. Of all women, four tested positive for at least two out of three markers: immunoglobulin A (IgA) antigliadin, immunoglobulin (IgG) antigliadin, and anti-endomysium antibodies, and underwent a jejunal biopsy; three had histological evidence of coeliac disease. One male partner was positive for two markers, and had a diagnostic jejunal biopsy. The prevalence of coeliac disease in infertile women seems higher (three out of 99, 3.03%) in the study group than in the general population (17 out of 1607, 1.06%), and particularly in the subgroup with unexplained infertility (two out of 25, 8%, P < 0.03). Screening for coeliac disease should be part of the diagnostic work-up of infertile women, particularly when no apparent cause can be ascertained after standard evaluation.

12 September 2017 in Pediatric Drugs
Verified
Journal Article
Closed access
PDF file
PTPaolo A. Tomasi
Paolo A. Tomasi
GEGunter F. Egger
Gunter F. Egger
CPChrissi Pallidis
Chrissi Pallidis
ASAgnes Saint-Raymond
Agnes Saint-Raymond

1 September 2011 in Pharmacological Research
Verified
Journal Article
Closed access
FRFrancesca Rocchi
Francesca Rocchi
PTPaolo Tomasi
Paolo Tomasi

18 January 2011 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
EMEfthymios Manolis
Efthymios Manolis
TOTariq Eldirdiry Osman
Tariq Eldirdiry Osman
RHRalf Herold
Ralf Herold
FKFranz Koenig
Franz Koenig
PTPaolo Tomasi
Paolo Tomasi
ARAgnes Saint Raymond
Agnes Saint Raymond

1 May 2017 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Closed access
PDF file
DPDobromir Penkov
Dobromir Penkov
PTPaolo Tomasi
Paolo Tomasi
IEIrmgard Eichler
Irmgard Eichler
DMDianne Murphy
Dianne Murphy
LYLynne P. Yao
Lynne P. Yao
JTJean Temeck
Jean Temeck

1 March 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
THThomas J Hwang
Thomas J Hwang
PTPaolo A Tomasi
Paolo A Tomasi
Florence BourgeoisFlorence Bourgeois
Florence Bourgeois
Few medicines have been approved for children, leading to rates of off-label prescribing reported to be as high as 90%. In 2007, the European Union adopted the Paediatric Regulation, which mandates that pharmaceutical companies conduct paediatric studies for all new medicines, unless granted a waiver. We aimed to evaluate the availability of paediatric trial results from studies required under the Paediatric Regulation for new medicines authorised in the EU. The European Medicines Agency (EMA) public database of paediatric investigation plans was searched for new medicines centrally authorised in the EU between 1 January 2010 and 31 December 2014 with at least 1 required paediatric study. For our study cohort of paediatric clinical trials required for these medicines, we used internal EMA databases and publicly available trial registries to determine changes to the planned completion date or study design, rates of trial completion, time to trial completion, and results reporting (peer-reviewed publication or posting on trial registry). Cox proportional hazards regression models were constructed to examine factors associated with study completion. A total of 326 paediatric clinical trials were required for 122 novel medicines authorised by the EMA between 2010 and 2014. In all, 76% (247/326) of paediatric studies were not planned to be completed until after the initial marketing authorisation. The planned completion dates for 50% (162/326) were further postponed by a median of 2.2 years. Overall, 38% (124/326) of paediatric studies were completed as of 30 November 2017. The rate of trial completion for paediatric studies planned to be completed after initial marketing authorisation was 23% (56/247), versus 86% (68/79) for trials planned to be completed before authorisation (adjusted hazard ratio 0.11; 95% CI 0.06–0.19). Among completed studies, the results were reported in a public registry or in the peer-reviewed literature for 85% (105/124) at a median of 1.1 years after study completion, and 60% (74/124) were published in a peer-reviewed journal. Limitations of this study include the potential lack of generalisability to medicines not authorised by the EMA and the possibility for more of these trials to be completed or published in the future. The completion of many paediatric studies required under the Paediatric Regulation has been delayed. Paediatric studies planned to be completed after marketing authorisation were associated with a lower likelihood of eventual completion, highlighting the need to examine the implementation of current policies in ensuring timely availability of important paediatric information.